Tyrosine kinase inhibitors as first-line treatment in NSCLC.
Department of Respiratory Medicine, Miyagi Cancer Center, 4-1 Nodayama Medeshima-shiote, Natori, Japan. Electronic address: maemondo-ma693@aioros.ocn.ne.jp.
Makoto
M
Maemondo
D002289:Carcinoma, Non-Small-Cell Lung; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D008175:Lung Neoplasms; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases